Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Links shared publicly online about this topic.
- 333total visits
Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion
Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) and Bayer HealthCare announced positive top-line results for VEGF Trap-Eye (aflibercept ophthalmic solution) in the Phase 3 GALILEO study in patients
View full resource at medicalnewstoday.com
Tags: Circulation, Healthcare, Pharma, Phase 3 Clinical Trial, Bayer
Most Recently Shared on April 28, 2011 at 7:05 am By:
Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion http://mnt.to/3V7b
Also Shared By:
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occlusion (CRVO) and in Phase 2 Study in Diabetic Macular Edema (DME) - Drugs.com MedNews
drugs.com — “In Phase 3 study in CRVO, 56 percent of VEGF Trap-Eye patients gained at least 15 letters of vision compared to 12 percent in control group VEGF Trap-Eye patien” View full resource at drugs.com
Most Recently Shared on December 20, 2010 at 3:01 pm By:
Drugs and Devices OW OW Health
Regeneron and Bayer Report Positive Results for VEGF Trap-Eye in Phase 3 Study in Central Retinal Vein Occ... http://bit.ly/gsAHQw #drug
Advertisement
MNT Eye Health
@mnt_eyehealth
Regeneron And Bayer Report Positive Results For VEGF Trap-Eye In Second Phase 3 Study In Central Retinal Vein Occlusion http://mnt.to/3V7b
1 year ago...